Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
about
Acquired pure red cell aplasia: updated review of treatmentThe pathogenesis and treatment of large granular lymphocyte leukemiaAutoimmune complications in chronic lymphocytic leukaemia (CLL).How I manage Evans Syndrome and AIHA cases in children.Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature.How I treat LGL leukemia.A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 studyDiseases of large granular lymphocytes.Anemia of Central Origin.Large granular lymphocytic leukaemia pathogenesis and management.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).Successful treatment of acquired pure red cell aplasia with oral corticosteroids in a patient with B-cell CLL.Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.Large granular lymphocyte leukemia: natural history and response to treatment.Chronic lymphocytic leukemia-associated pure red cell aplasia.Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia.
P2860
Q24652253-DBEDB805-47C8-47CA-BBD2-6482DF3A31B2Q30405429-3E7B669F-92C1-4059-814E-3A2F17FA9EAEQ33390656-1D1BEA12-CC95-4896-8FDE-32F1822226F4Q33428041-1E6035A7-4C89-4967-9AD5-FA148921491FQ33762085-CDA7B017-3D0E-41E7-B086-0BCFCB991B1BQ34707130-205FD0A0-B7C0-42F3-B15B-529F1600DCD6Q36194538-979E8793-A5DC-4EDE-AC2D-1041168E1DCAQ36486302-446FFA51-DA7B-4D97-B81F-864413FAF636Q36771233-7A5A4925-D9E8-4DD7-BA1A-43693855CA74Q36784115-3485BACE-F07D-44EC-8518-43887862C177Q37821049-97605587-51AA-4638-8A2D-484E8ECA03A7Q37843939-5714CA0E-EDFB-46D0-9815-C97DE134AAEFQ37863688-DF1562FC-65FB-4A35-8974-0784677B4056Q38065877-C8D2229F-6151-4050-A890-81A5D474C21BQ41964792-F87931AB-9ABC-4C4D-AE66-5B61C86DA6FBQ42574009-0D92E47D-4A21-4DB8-8E74-CFDB1D46BFC8Q43109504-A1279980-B38A-4205-89CA-973D4D64C0EBQ50606472-FF913FA5-BA98-488F-9D67-76F152B8A73AQ50753588-56F4F000-29DA-4697-9D09-A3EFDA6D691FQ53889648-1992D04A-17BF-4935-9DB3-03EC3E16F59F
P2860
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Successful treatment of refrac ...... body alemtuzumab (Campath-1H).
@en
Successful treatment of refrac ...... onoclonal antibody alemtuzumab
@nl
type
label
Successful treatment of refrac ...... body alemtuzumab (Campath-1H).
@en
Successful treatment of refrac ...... onoclonal antibody alemtuzumab
@nl
prefLabel
Successful treatment of refrac ...... body alemtuzumab (Campath-1H).
@en
Successful treatment of refrac ...... onoclonal antibody alemtuzumab
@nl
P1476
Successful treatment of refrac ...... body alemtuzumab (Campath-1H).
@en
P2093
Howard A Liebman
Xiuqing Ru
P304
P356
10.1046/J.1365-2141.2003.04609.X
P407
P577
2003-10-01T00:00:00Z